Mostrar el registro sencillo del documento

dc.creatorShi, Rui
dc.creatorShan, Chao
dc.creatorDuan, Xiaomin
dc.creatorChen, Zhihai
dc.creatorLiu, Peipei
dc.creatorSong, Jinwen
dc.creatorSong, Tao
dc.creatorBi, Xiaoshan
dc.creatorHan, Chao
dc.creatorWu, Lianao
dc.creatorGao, Ge
dc.creatorHu, Xue
dc.creatorZhang, Yanan
dc.creatorTong, Zhou
dc.creatorHuang, Weijin
dc.creatorLiu, William Jun
dc.creatorWu, Guizhen
dc.creatorZhang, Bo
dc.creatorWang, Lan
dc.creatorQi, Jianxun
dc.creatorFeng, Hui
dc.creatorWang, Fu sheng
dc.creatorWang, Qihui
dc.creatorGao, George Fu
dc.creatorYuan, Zhiming
dc.creatorYan, Jinghua
dc.date.accessioned2020-07-17T23:49:36Z
dc.date.available2020-07-17T23:49:36Z
dc.date.created2020-05-26
dc.identifier.issn1476-4687spa
dc.identifier.otherhttps://www.nature.com/articles/s41586-020-2381-yspa
dc.identifier.urihttp://hdl.handle.net/20.500.12010/10823
dc.format.extent26 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.publisherScience Directeng
dc.sourcereponame:Expeditio Repositorio Institucional UJTLspa
dc.sourceinstname:Universidad de Bogotá Jorge Tadeo Lozanospa
dc.subjectAnticuerpos neutralizantes humanosspa
dc.titleA human neutralizing antibody targets the receptor-binding site of SARS-CoV-2spa
dc.type.localArtículospa
dc.subject.lembSíndrome respiratorio agudo gravespa
dc.subject.lembCOVID-19spa
dc.subject.lembSARS-CoV-2spa
dc.subject.lembCoronavirusspa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.type.hasversioninfo:eu-repo/semantics/acceptedVersionspa
dc.subject.keywordHuman neutralizing antibodyspa
dc.identifier.doihttps://doi.org/10.1038/s41586-020-2381-yspa
dc.description.abstractenglishAn outbreak of coronavirus disease 2019 (COVID-19)1,2,3, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4, has spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. Here we report the isolation of two specific human monoclonal antibodies (termed CA1 and CB6) from a patient convalescing from COVID-19. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro. In addition, CB6 inhibited infection with SARS-CoV-2 in rhesus monkeys in both prophylactic and treatment settings. We also performed structural studies, which revealed that CB6 recognizes an epitope that overlaps with angiotensin-converting enzyme 2 (ACE2)-binding sites in the SARS-CoV-2 receptor-binding domain, and thereby interferes with virus–receptor interactions by both steric hindrance and direct competition for interface residues. Our results suggest that CB6 deserves further study as a candidate for translation to the clinic.spa


Archivos en el documento

Thumbnail

Este documento aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del documento